Combined chronic blockade of hyper-active L-type calcium channels and NMDA receptors ameliorates HIV-1 associated hyper-excitability of mPFC pyramidal neurons.
Human Immunodeficiency Virus type 1 (HIV-1) infection induces neurological and neuropsychological deficits, which are associated with dysregulation of the medial prefrontal cortex (mPFC) and other vulnerable brain regions. We evaluated the impact of HIV infection in the mPFC and the therapeutic potential of targeting over-active voltage-gated L-type Ca(2+) channels (L-channel) and NMDA receptors (NMDAR), as modeled in HIV-1 transgenic (Tg) rats. Whole-cell patch-clamp recording was used to assess the membrane properties and voltage-sensitive Ca(2+) potentials (Ca(2+) influx) in mPFC pyramidal neurons. Neurons from HIV-1 Tg rats displayed reduced rheobase, spike amplitude and inwardly-rectifying K(+) influx, increased numbers of action potentials, and a trend of aberrant firing compared to those from non-Tg control rats. Neuronal hyper-excitation was associated with abnormally-enhanced Ca(2+) influx (independent of NMDAR), which was eliminated by acute L-channel blockade. Combined chronic blockade of over-active L-channels and NMDARs with open-channel blockers abolished HIV effects on spiking, aberrant firing and Ca(2+) potential half-amplitude duration, though not the reduced inward rectification. In contrast, individual chronic blockade of over-active L-channels or NMDARs did not alleviate HIV-induced mPFC hyper-excitability. These studies demonstrate that HIV alters mPFC neuronal activity by dysregulating membrane excitability and Ca(2+) influx through the L-channels. This renders these neurons more susceptible and vulnerable to excitatory stimuli, and could contribute to HIV-associated neuropathogenesis. Combined targeting of over-active L-channels/NMDARs alleviates HIV-induced dysfunction of mPFC pyramidal neurons, emphasizing a potential novel therapeutic strategy that may effectively decrease HIV-induced Ca(2+) dysregulation in the mPFC.
Department of Pharmacology, Rush University Medical Center, Chicago, IL 60612, United States.
Christina E
CE
Khodr
Department of Pharmacology, Rush University Medical Center, Chicago, IL 60612, United States.
Lihua
L
Chen
Department of Pharmacology, Rush University Medical Center, Chicago, IL 60612, United States.
Sonya
S
Dave
Department of Immunology and Microbiology, Rush University Medical Center, Chicago, IL 60612, United States.
Lena
L
Al-Harthi
Department of Pharmacology, Rush University Medical Center, Chicago, IL 60612, United States. Electronic address: xiu-ti_hu@rush.edu.
Xiu-Ti
XT
Hu
D000818:Animals; D020746:Calcium Channels, L-Type / Q000378:metabolism*; D015658:HIV Infections / Q000378:metabolism; D015497:HIV-1; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D008822:Mice, Transgenic; D018408:Patch-Clamp Techniques / Q000379:methods; D017397:Prefrontal Cortex / Q000378:metabolism* / Q000821:virology; D017966:Pyramidal Cells / Q000378:metabolism / Q000821:virology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*
D020746:Calcium Channels, L-Type; D016194:Receptors, N-Methyl-D-Aspartate
Calcium; Calcium channel blockade; HAND; HIV; L-channel; Medial prefrontal cortex; NMDAR; Pyramidal neuron